News
Events
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
2024/01/05
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
2023/12/29
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
2023/10/27
LumiraDx Partners with Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
2023/10/24
LumiraDx Reports Second Quarter 2023 Results
2023/08/24
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
2023/08/16
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
2023/07/31
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
2023/06/30
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
2023/06/15
LumiraDx Reports First Quarter 2023 Results
2023/05/16
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
2023/05/09
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
2023/04/24
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
2023/04/06
Boots UK announce plans to pilot a diabetes screening service powered by the LumiraDx HbA1c Test
2023/03/24
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
2023/03/21
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21 2023
2023/03/14
LumiraDx to Present at Raymond James Institutional Investors Conference
2023/03/03
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
2023/02/17
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
2023/02/06
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
2023/01/31
LumiraDx latest cost reduction program continues progress toward operating cash flow breakeven by the end of 2023
2022/12/19
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
2022/12/15
LumiraDx Receives CTDA Approval for its LumiraDx Dual-Target SARS-CoV-2 STAR Complete
Health Tech World: Driving change in healthcare using point-of-care diagnostics
2022/12/14
Lab Pulse: Bill & Melinda Gates Foundation awards $14.2M in grants to LumiraDx to develop TB testing system
Clinical Services Journal: Adopt point of care testing to cut carbon emissions, say over 80% of GPs
2022/12/08
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings
ET Health World: LumiraDx launches C-Reactive Protein test to combat antimicrobial resistance in India
2022/11/24
Health Tech World: LumiraDx continues expansion of HbA1c test
2022/11/14
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
2022/10/12
Health Europa: Diagnostic technology is central to tackling pandemics
2022/09/22
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Medical Product Outsourcing: Integrating Point of Care to Future Proof our Community Health System
2022/09/16
LumiraDx Awarded Rapid Testing Agreement with Premier, Inc.
2022/09/08
KevinMD: Immediate, accurate diagnosis is crucial to the future of equitable patient care
2022/08/29
Health Tech World: LumiraDx COVID-19 antigen test alone in exceeding WHO target in Cochrane Review
2022/08/25
Health Europa: LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
LumiraDx to Present on Impact of its Next-Generation Microfluidic Technology at American Association for Clinical Chemistry (AACC) Annual Conference in Chicago
2022/07/25
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
2022/07/21
LumiraDx Announces Proposed Public Offering of Common Shares
2022/07/19
London Loves Business: Groundbreaking Covid test gives lifeline to businesses as cases soar
2022/06/30
HealthTech World: The versatile diagnostic platform that passes the test
2022/06/14
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
2022/06/08
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
2022/06/02
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
2022/05/26
Medical Device Network: LumiraDx’s HbA1c test receives CE mark for diabetes screening
HealthTech World: LumiraDx receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
MD+DI: LumiraDx Scores CE Mark for Fast POC COVID-19 Test
2022/05/24
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
2022/05/19
HealthTech World: Antimicrobial resistance: New guidance on using CRP tests in primary care to reduce antibiotic overprescribing
2022/05/18
Bill Gates Ted Talk: We Can Make COVID-19 the Last Pandemic | Bill Gates | TED
2022/04/29
Health Europa: Answering healthcare needs with point-of-care testing
2022/04/26
Forbes: Could The Innovation Stack Revolutionize Your Industry?
2022/04/15
Fast Company: Bill Gates wants to create a global pandemic first response team
2022/04/12
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
2022/03/01
LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete
2022/02/21
Health Europa: LumiraDx: Fighting antimicrobial resistance with innovative POC testing
2022/01/26
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
2021/10/20
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
2021/09/28
Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19
2021/09/21
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
2021/08/20
PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate
2021/08/18
LumiraDx Launches first-of-its-kind smart Diagnostic platform
2019/08/29
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.